Combinations of iOnctura's roginolisib revert immune suppression in immunotherapy-resistant NSCLC
Late breaking data from ongoing Phase I/II PULMO-01, the first clinical study of conformation-selective PI3Kδ inhibitor roginolisib in immunotherapy-resistant non-small cell lung cancer (NSCLC), presented at SITC Data demonstrated roginolisib-containing regimens were tolerable, reduced...
Covered in this story
Call it yourself
No calls on $SITC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Site Centers Corp →Dalsna Finance is currently tracking 6 stories mentioning Site Centers Corp, the earliest published 6 Nov 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.